Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-022 vs Chlorambucil + Rituximab in Untreated CLL/SLL
NCT04578613Phase 3Unknown
- Sponsor
- InnoCare Pharma
- Start
- Jan 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orelabrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by InnoCare Pharma. Status: unknown.
02
Drugs
orelabrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04578613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04578613.